<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762799</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-002-1</org_study_id>
    <nct_id>NCT02762799</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®</brief_title>
  <official_title>Single-center Open Randomized Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® (JSC &quot;BIOCAD&quot;, Russia) Compared to Neupogen® (F. Hoffman-La Roche Ltd., Switzerland)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety
      of single-injection of Leucostim® to healthy volunteers compared to Neupogen®
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-48 hours), AUC (0-∞)</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Area Under Curve (AUC) &quot;concentration - time&quot; from the moment of filgrastim injection to 48 hours and to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax after subcutaneous injection</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Maximal concentration of filgrastim after subcutaneous injection of filgrastim</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax after intravenous injection</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Maximal concentration of filgrastim after intravenous injection of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax after injection</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Time after single injection to reach maximal concentration of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Т½</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Half-life of filgrastim after single injection of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>The elimination rate constant after single injection of filgrastim</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>0 to 48 hours post-dose</time_frame>
    <description>Clearance of filgrastim after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC-AUEC (0-336 hours)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANC-Emax</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Maximal absolute neutrophil count after single filgrastim injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34-AUEC (0-336 hours)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Area Under Effect Curve (AUEC) &quot;effect - time&quot; from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34-Emax</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Maximal absolute count of CD34-cells after single filgrastim injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall frequency of serious adverse events (SAE)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall frequency of adverse events (AE)</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of local reactions</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE/SAE 3-4 grade CTCAE 4.03</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of preliminary withdrawal due to AE/SAE</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with binding or neutralizing antibodies to filgrastim</measure>
    <time_frame>0 to 336 hours post-dose</time_frame>
    <description>Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leucocytosis</condition>
  <arm_group>
    <arm_group_label>Leucostim® --&gt; Neupogen®, subcutaneous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neupogen® --&gt; Leucostim®, subcutaneous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leucostim® --&gt; Neupogen®, intravenous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neupogen® --&gt; Leucostim®, intravenous injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Leucostim®</intervention_name>
    <description>Leucostim® is filgrastim biosimilar.</description>
    <arm_group_label>Leucostim® --&gt; Neupogen®, subcutaneous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, subcutaneous injections</arm_group_label>
    <arm_group_label>Leucostim® --&gt; Neupogen®, intravenous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, intravenous injections</arm_group_label>
    <other_name>filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Neupogen®</intervention_name>
    <arm_group_label>Leucostim® --&gt; Neupogen®, subcutaneous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, subcutaneous injections</arm_group_label>
    <arm_group_label>Leucostim® --&gt; Neupogen®, intravenous injections</arm_group_label>
    <arm_group_label>Neupogen® --&gt; Leucostim®, intravenous injections</arm_group_label>
    <other_name>filgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Male gender.

          -  Age between 18 and 45 years.

          -  Normal body mass index.

          -  Verified diagnosis &quot;healthy&quot;, established according to the anamnesis, physical
             examination and laboratory findings.

          -  Absence of alcohol or drug abuse.

        Exclusion Criteria:

          -  History of use of filgrastim.

          -  Allergy to any components of study drugs.

          -  Acute hemorrhage, donation of blood / plasma or blood transfusions during last 2
             months prior to enrollment in the study, history of chronic bleeding.

          -  Surgical interventions during last 30 days prior to screening or planed surgical
             intervention during the study.

          -  Any diseases that could interfere with pharmacokinetics of filgrastim, including
             chronic liver, liver or blood diseases, diseases of cardiovascular, lung and
             neuroendocrine systems.

          -  Fever with body temperature higher than 40°С.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neutrophil count</keyword>
  <keyword>filgrastim</keyword>
  <keyword>granulocyte colony-stimulating factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukocytosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 6, 2018</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 26, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

